Patrick Mauro Investment Advisor INC. cut its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 74.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,225 shares of the biopharmaceutical company’s stock after selling 35,387 shares during the period. Patrick Mauro Investment Advisor INC.’s holdings in Bristol Myers Squibb were worth $763,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in BMY. BlackRock Inc. boosted its holdings in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp increased its position in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after buying an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Trading Down 0.1%
NYSE BMY opened at $63.39 on Monday. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The stock has a 50-day moving average of $61.90 and a 200-day moving average of $60.31. The firm has a market cap of $129.57 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 0.33 and a beta of 0.20.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period last year, the company earned $1.63 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.88%.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and issued a $76.00 target price on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 13th. Zacks Research downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Wells Fargo & Company decreased their price target on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 13th. Finally, Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $73.00 to $59.00 in a research note on Monday, October 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $65.46.
View Our Latest Research Report on BMY
Insider Activity at Bristol Myers Squibb
In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by company insiders.
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
